Megestrol acetate was one of the first progestational agents to be evaluated for use in the hormonal therapy of advanced breast cancer. As single-agent therapy, the average overall response rate to megestrol acetate therapy is 30%[3]. Megestrol acetate doses equal to or lower than 240 mg/day lead to slight weight gain in patients with cancer-associated cachexia[4]. The mechanism of action of megestrol is believed to involve stimulation of appetite by both direct and indirect pathways and antagonism of the metabolic effects of the principal catabolic cytokines[5]. The risk of megestrol-induced Cushing syndrome, especially with high doses of the medication, should be considered as a possible adverse effect in patents with renal insufficiency[6].
Megestrol acetate/醋酸甲地孕酮 细胞实验
Cell Line
Concentration
Treated Time
Description
References
ECC-1 cells
75 μM
24 h
To study the effect of combining megestrol acetate with pterostilbene on endometrial cancer cell growth, the results showed that the combination significantly enhanced apoptosis and cell cycle inhibition.
Sci Rep. 2017 Oct 6;7(1):12754.
HEC-1A cells
75 μM
24 h
To study the effect of combining megestrol acetate with pterostilbene on endometrial cancer cell growth, the results showed that the combination significantly enhanced apoptosis and cell cycle inhibition.
Sci Rep. 2017 Oct 6;7(1):12754.
Endometrial cancer patient-derived organoids
1 µM
2 weeks
To evaluate the inhibitory effect of Megestrol on the growth of endometrial cancer organoids, results showed that Megestrol did not significantly inhibit organoid growth.
Int J Gynecol Cancer. 2017 Oct;27(8):1701-1707.
Megestrol acetate/醋酸甲地孕酮 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Nude mice
HEC-1A xenograft model
Oral gavage
10 mg/kg
Daily for 5 weeks
To study the effect of combining megestrol acetate with pterostilbene on tumor growth in an endometrial cancer xenograft model, the results showed that the combination significantly inhibited tumor growth.
Sci Rep. 2017 Oct 6;7(1):12754.
Nude mice
Ovarian cancer model
Subcutaneous injection
250 µg
Daily, for 28 days
To study the effect of Megestrol on ovarian cancer growth, results showed that the combination of Megestrol with 17β-estradiol restored tumor burden to near control levels.
搜索
